Login to Your Account

Washington Roundup

Dificid Taps into CMS' New Technology Payment Program

By Mari Serebrov
Washington Editor

Monday, August 6, 2012
WASHINGTON – Optimer Pharmaceuticals Inc.'s Dificid hit the market a few years too soon to take advantage of the exclusivity offered for new antibiotics under the FDA Safety and Innovation Act (FDASIA), but the Clostridium difficile-fighting drug is getting a regulatory hand up from another agency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription